

Figure 1

		_	_		-			• •			_	cyı	OIL	56	dae	псе	:5	
GAG	GTT	CAG	CTG	CAG	CAG	TCT	GGG	GCA	GAG	CTT	GTG	AAG	CCA	GGG	GCC.	ሞርኔ	GTC	
Glu	Val	Gln	Leu	Gln	Gln	Ser	Gly	Ala	Glu	Leu	Val	Lys	Pro	Gly CDR1	Ala	Ser		18
AGG	TTG	TCC	TGC	ACA	GCT	TCT	GGC	TTC	AAC	ATT	AAA	GAC	ACC	TAT	ATG	CAC	TGG	
Arg	Leu	Ser	Cys	Thr	Ala	Ser	Gly	Phe	Asn	Ile	Lys	Asp	Thr	Tyr	Met	His	Trp	36
																CD	32	
Val	TIA	GAG	AGG	Dro.	GAA	CAG	GGC Gly	CTG	GAG	TGG	ATT	GGA	AGG	ATT	GAT	CCT	GCG	
			1119		GIU	GIII	GLY	nea	GIU	TIP	TTE	GIĀ	Arg	IIe	Asp	Pro	Ala	54
AAT	GGT	AAT	ACT	AAA	TGT	GAC	CCG	AAG	TTC	CAG	GGC	AAG	GCC	ACT	АТА	ACA	GCA	
Asn	Gly	Asn	Thr	Lys	Cys	Asp	Pro	Lys	Phe	Gln	Gly	Lys	Ala	Thr	Ile	Thr	Ala	72
GAC	ACA	TCC	TCC	AAC	ACA	GCC	TAC	CTG.	CAG		NCC.	300	cmc	3.03				
Asp	Thr	Ser	Ser	Asn	Thr	Ala	Tyr	Leu	Gln	Leu	Ser	Ser	Len	Thr	Sar	GAG	Acn	90
													CDI	23			-	50
ACT	GCC	GTC	TAT	TAC	TGT	TCT	AGA	GAG	GTC	CTA	ACT	GGG	ACG	TGG	TCT	TTG	GAC	
THE	ALA	Val	172	JYT	Cys	Ser	Arg	Glu	Val	Leu	Thr	Gly	Thr	Trp	Ser	Leu	Asp	108
TAC	TGG	GGT	CAA	GGA	ACC	TCA	GTC	ACC	GTC	TCC	TCA							
Tyr	Trp	Gly	Gln	Gly	Thr	Ser	Val	Thr	Val	Ser	Ser							120
NR	-LU	-13	L	igh	t d	cha:	in	vai	ria	ble	re	gi	on	sec	que:	nce	s	
GAC	ATC	CAG	ATG	ATT	CAG	TCT	CCA	TCG	TCC	ATG	TTT	GCC	TCT	CTG	GGA	GAC	AGA	
Asp	Ile	Gln	Met	Ile	Gln	Ser	Pro	Ser	Ser	Met CDR1	Phe	Ala	Ser	Leu	Gly	Asp	Arg	18
GTC	AGT	CTC	TCT	TGT	CGG	GCT	AGT	CAG	GGC	ATT	AGA	GGT	таа	בידים	GAC	mcc.	ጥልጥ	
Val	Ser	Leu	Ser	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Arg	Gly	Asn	Leu	ozA	Tro	Tvr	36
															•	יחם?		
CAG Gln	CAG Gla	LARA	CCA	GGT	GGA	ACT	ATT	AAA	CTC	CTG	ATC	TAC	TCC	ACA	TCC	AAT	TTA	
		nys	110	GIY	GTĀ	THE	Ile	гĀг	ren	Leu	TTE	Tyr	Ser	Thr	Ser	Asn	Leu	54
AAT	TCT	GGT	GTC	CCA	TCA	AGG	TTC	AGT	GGC	AGT	GGG	TCT	GGG	TCA	GAT	TAT	TCT	
Asn	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Ser	qzA	Tyr	Ser	72
CTC	ACC	ATC	AGC	AGC	CTA	GAC	TCT	GAA	GAT	datas	GC3	G3C	mam	ma c	mcm	CM3	C3.C	
Leu	Thr	Ile	Ser	Ser	Leu	Asp	Ser	Glu	Asp	Phe	Ala	Asp	Tvr	Tvr	Cvs	Leu	Gln	90
	CI	2R.3																
CGT	AAT	GCG	TAT	CCG	TAC	ACG	TTC	GGA	GGG	GGG	ACC	AAG	CTG	GAA	ATA	AAA		
vr.a	AST	WTS	IÄI	rro	TAL	THE	Phe	GTĀ	GIA	Gly	Thr	Lys	Leu	Glu	Ile	Lvs		107

Figure 2

				Light	chain				
1 ASP	ILE	GLN	MET	5 THR	GLN	SER	PRO	SER	10 SER
11 LEU	SER	ALA	SER	15 VAL	GLY	ASP	ARG	VAL	20 THR
21 ILE	THR	CYS	ARG	25 ALA	SER	GLN	GLY	ILE	30 ARG
GLY GLY	ASN	LEU	ASP	35 TRP	TYR	GLM	GLN	LYS	40 PRO
41 GLY	LYS	GLY	PRO	45 LYS	LEU	LEU	ILE	TYR	50 SER
51 THR	SER	ASN	LEU	55 ASN	SER	GLY	VAL	PRO	60 SER
61 ARG	PHE	SER	GLY	65 SER	GLY	SER	GLY	SER	70 ASP
71 TYR	THR	LEU	THR	75 ILE	SER	SER	LEU	GLN	80 PRO
GLU GLU	ASP	PHE	ALA	85 THR	TYR	TYR	CYS	LEU	gln gln
91 ARG	ASN	ALA	TYR	95 PRO	TYR	THR	PHE	GLY	GLN GLN
GLY	THR	LYS	LEU	105 GLU	ILE	LYS			

The humanised sequence of NRX451 light chain, residue positions which differ between NR-LU-13.8 NRX451-humanised are marked with bold type.

Figure 3

				Heav	y chain				
GLN	VAL	GLN	LEU	VAL.	GLN	SER	GLY	ALA	10 GLU
VAL	LYS	LYS	PRO	15 GLY	ALA	SER	VAL	LYS	20 VAL
21 SER	CYS	LYS	ALA	25 SER	GLY	PHE	ASN	ILE	LYS
31 ASP	THR	TYR	MET	HIS	TRP	VAL	ARG	GLM	ALA
41 PRO	GLY	GLN	GLY	45 LEU	GLN	TRP	MET	GLY	50 ARG
51 ILE	ASP	PRO	ALA	asn	GLY	asn	THR	LYS	CYS
61 ASP	LEU	SER	PHE	GLN GLN	GLY	ARG	VAL	THR	70 ILE
71 THR	ALA	ASP	THR	75 SER	ILE	ASN	THR	ALA	80 TYR
81 MET	GLU	LEU	SER	85 SER	LEU	ARG	SER	ASP	90 ASP
91 THR	ALA	VAL	TYR	95 TYR	CYS	SER	ARG	GLU	100 VAL
LEU	THR	GLY	THR	105 TRP	SER	LEU	ASP	TYR	110 TRP
111 GLY	GLN	GLY	THR	115 LEU	VAL	THR	VAL	SER	120 Ser

The humanized sequence of NRX451 heavy chain, residue positions which differ between NR-LU-13 and NRX451-humanised are marked with bold type.

Figure 4

Alignment of the Light Chain Variable Regions of NR-LU-13 (top) and humanized NRX451 (bottom).

DIQMISSPSSMFASLGDRVSLSC PASQUIRGHLD WYQQXPGGTIKLLIY SISHLMS
DIQMIQSPSSLSASVGDRVITITC PASQUIRGHLD WYQQXPGKGPKLLIY SISHLMS
DIQMIQSPSSLSASVGDRVITITC DAY

GVPSRFSGSGSGSDYTLTISSLESEDFADYYC LORNAYPYTF GGGTKLEIK

GVPSRFSGSGSGSDYTLTISSLQPEDFATYYC LORNAYPYTF GQGTKLEIK

CDR3

Alignment of the Heavy Chain Variable Regions of NR-LU-13 (top) and humanized NRX 451 (bottom)

EVQLQQSGAELVKFGASVRLSCTASGFNIK DTYMH WVIERPEQGLEWIG
QVQLVQSGAEVKKPGASVKVSCKASGFNIK DTYMH WVRQAPGQGLQWMG

RIDPANGNTK CDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCS
RIDPANGNTK CDLSFQGRVTITADTSSNTAYMELSSLRSDDTAVYYCS
CDR2

REVLTGTWSLDY WGQGTLVTVSS
REVLTGTWSLDY WGQGTLVTVSS
CDR3




Figure 6

Same frequencies but matching with human sequences. Only one occurence of λ sp at position 182 is found and no occurences of λ sp at position 181.

RES	181	182
A	-	0.48
R	-	0.02
N	0.01	0.18
D	0.00	0.00
C	0.00	0.00
Q E	0.00	-
E	-	-
G	0.00	0.01
H	0.00	-
I	-	0.00
L	-	0.00
K	0.00	0.00
M	-	-
F	0.03	-
P	0.00	0.01
s	0.01	0.23
T	-	0.02
W	0.00	-
Y	0.91	-
V	0.00	0.02
x	0.01	0.02
0	-	
-	-	-
Z	-	-
В	-	0.00
Total	1.00	1.00

FIGURE IN CO. TO A SERVICE AND A SERVICE AND

Figure 7A

Sequence positions 50 and 183 are structural mutations within 5 $\tt A$ of the CDR's. Frequency of residue types at these positions are identical.

Position 50 (153 human lambda sequences)

RES	50
A	
R	-
N	
	_
ē	_
ŏ	-
Ř	-
D C Q B G	
H	-
ī	0.00
L	
L L K	-
M	0.00
F P	-
P	0.93
S T	-
T	-
W	-
Y V	-
v	-
X	0.06
X 0 -	-
	0.93
Z	-
В	-
Total	1.00

Figure 7B

Position 50 (279 human kappa sequences)

RES	50
A	0.00
R	-
N	-
D	-
D C	_
ŏ	:
Q B	_
Ğ	
н	-
ū	
I	0.00
L	0.00
K	-
M	- - 0.96
F	-
P	0.96
S	-
Ť	-
W	-
Ÿ	_
Y V	0.03
÷	0.02
X O	0.03
-	-
-	-
z	-
В	-
Total	1.00

Figure 7C

Position 50 is highly conserved in all the sequences but proline can be exchanged by Ile or Leu. The framework used for the light chain (sfab) does have an Ile at this position. If this position is compared to other structures the backbone torsions are the same for structures with a Pro and an Ile at this position.

Position 183 (561 human sequences)

RES	183
Α	0.06
R	
N	0.00
D	0.21
D C Q	-
Q	0.15
E	0.01
G	0.01
H	
I L	0.00
ĸ	0.00
M	0.00
F	0.00
P	0.40
s	0.01
T	0.01
W	-
Y	0.00
v	0.08
x	0.02
0	-
-	-
Z B	
D	0.00
Total	1.00

Position	183	(1210	MOIIGA	gamiancas)

RES	183
A	0.16
R	0.00
N	0.00
D	0.13
D C	-
Q	0.16
Ē	0.25
Ğ	0.02
H	0.02
Î .	
÷	-
<u>r</u>	-
K	0.00
M	-
F	-
P	0.17
S	0.08
T	0.00
W	-
Y	-
V	0.00
x	0.02
Ö	
-	-
z	=
	-
В	-
Total	1.00

Leu is seen in human sequences at this position, but never in murine sequences, for both human and murine Sequences P is the most frequently occuring residue at position 183.

Figure 7E

Comments for pcDNA3: 5446 nucleotides

CMV promoter: bases 209-863 T7 promoter: bases 864-882 Polylinker: bases 889-994 Spé promoter: bases 999-1016 BGH poly A: bases 1018-1249 SV40 promoter: bases 1790-2115

SV40 origin of replication: bases 1984-2069 Neomycin ORF: bases 2151-2945 SV40 poly A: bases 3000-3372 ColE1 origin: bases 3632-4305 Ampicilin ORF: bases 4450-5310




Figure 8




Figure 9




Figure 10





Figure 11

Express Mail No.: EV064839733US
Title: HUMANIZED ANTIBODIES THAT BIND TO THE ANTIGEN BOUND BY
ANTIBODY NR-LU-13 AND THEIR USE IN PRETARGETING METHODS







Figure 13

Express Mail No.: EV064839733US

Title: HUMANIZED ANTIBODIES THAT BIND TO THE ANTIGEN BOUND BY
ANTIBODY NR-LU-13 AND THEIR USE IN PRETARGETING METHODS
Inventors: Scott S. Graves et al. Serial No.: Not yet assigned Docket No.: 690022.527C2



Express Mail No.: EV064839733US
Title: HUMANIZED ANTIBODIES THAT BIND TO THE ANTIGEN BOUND BY
ANTIBODY NR-LU-13 AND THEIR USE IN PRETARGETING METHODS
Inventors: Scott S. Graves et al. Serial No.: Not yet assigned Docket No.: 690022.527C2




Figure 15a




Figure 15b




Figure 15c




Figure 15d




Figure 16a





Figure 16b



Ratio of ox/red NRX451-125 to NRX451-131




Figure 17

THE REPORT OF THE REAL PROPERTY AND AND ADDRESS OF THE PERSON ADDRESS OF THE PERSON AND ADDRESS OF THE PERSON AD





Figure 19



Express Mail No.: EV064839733US
Title: HUMANIZED ANTIBODIES THAT BIND TO THE ANTIGEN BOUND BY
ANTIBODY NR-LU-13 AND THEIR USE IN PRETARGETING METHODS
Inventors: Scott S. Graves et al. Serial No.: Not yet assigned Docket No.: 690022.527C2

Express Mail No.: EV064839733US
Title: HUMANIZED ANTIBODIES THAT BIND TO THE ANTIGEN BOUND BY
ANTIBODY NR-LU-13 AND THEIR USE IN PRETARGETING METHODS
Inventors: Scott S. Graves et al. Serial No.: Not yet assigned Docket No.: 690022.527C2




Figure 21a

THE REPORT OF THE PARTY OF THE

Figure 21b




Figure 22




Figure 23




Figure 24a




Figure 24b